It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

A spin-out from Sheffield that uses stem cells to help with conventional drug discovery is looking for investment to continue pre-clinical research on therapeutic applications and business development activities.

Avidex is teaming up with diabetes specialists at King’s College London to work on a new approach to treating the Type I form of the disease.

Oslo-based anticancer company Algeta has closed a series A financing round totaling €23 million.

Imperial College London's technology commercialisation company is betting on a spin-out company, deltaDOT, to speed detection and decrease costs of finding new proteins for drug discovery.

A new life-science fund said it raised €240.3 million – and promptly announced its first two investments.